No Data
H.C. Wainwright Maintains Oramed Pharmaceuticals(ORMP.US) With Hold Rating
H.C. Wainwright analyst Ram Selvaraju maintains $Oramed Pharmaceuticals(ORMP.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 40.8% and a total average return of 0
Oramed Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Oramed Pharmaceuticals (ORMP): Shareholder Letter Spurs Bullish Trend
Oramed Pharmaceuticals Shares Are Trading Higher After the Company Announced a $20 Million Buyback Program and Finalized Its Joint Venture With Hefei Tianhui Biotech.
Express News | Oramed Pharmaceuticals: Htit Committing $70 Mln in Cash, Co Investing $25 Mln in Cash & Stock in Jv
Express News | Oramed Pharmaceuticals Inc: Jv With Chinese Partner, Htit